Disease areas
Cardiology
Mapping prevention, diagnostics and access pathways for cardiovascular care.
Cardiometabolic
Tracking risk, prevention and access in metabolic and vascular health.
Eye Disease
Following diagnostics, treatment access and equity in vision care.
Infectious disease
Tracking diagnostics, resistance, prevention and access across infection pathways.
Neurology
Mapping early diagnosis, biomarkers and access in brain health.
Oncology
Following testing, treatment access and equity across cancer pathways.
Cardiology
See all →
Plastic in the coronary bloodstream: micro- and nanoplastics raise a new cardiovascular warning
Military recruits appear to face far more sudden cardiac death than athletes. Screening still depends on the country
Singapore wants healthcare AI that does not think like the West. Cardiometabolic care is its first real test
AI can flag hidden cardiac risk. The dangerous part is what health systems do next
Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence
AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?
Beans for men, broccoli for women? The real cardiometabolic warning is that risk starts by 22
Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing
Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge
Ultra-processed food may leave a metabolic fingerprint in the blood.
Cardiometabolic
See all →
The baby sets the schedule. Postpartum diet advice still pretends mothers control the clock
Singapore wants healthcare AI that does not think like the West. Cardiometabolic care is its first real test
Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence
Beans for men, broccoli for women? The real cardiometabolic warning is that risk starts by 22
Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing
Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge
Ultra-processed food may leave a metabolic fingerprint in the blood.
Sugar substitutes were sold as metabolic shortcuts. The evidence is getting harder to ignore
Same country, different risks: why Iranian women’s heart disease profiles expose a blind spot in prevention policy
Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate
Eye Disease
See all →Singapore wants healthcare AI that does not think like the West. Cardiometabolic care is its first real test
El Salvador Eliminated Trachoma. The Certificate Is Not The Finish Line.
The Most Preventable Cause of Vision Loss May Still Be Smoking
Cellular Reprogramming Enters Neuro-Ophthalmology
Not All Eye Infections Are Equal: New Evidence Points to a Precision Medicine Approach
The Air We Breathe May Be Shaping the Future Burden of Blindness
Ozempic and Eye Health: Balancing Metabolic Benefits with Vision Risks
Diabetic Eye Screening Is Becoming Risk-Based
Abu Dhabi Puts Rare Eye Gene Therapy on the Regional Map
AI Eye Screening Has an Image Quality Problem
Infectious disease
See all →
India Approved Its First Dengue Vaccine. Access Is Still Unwritten.
Canada Chose An Ebola Travel Ban. WHO Warned Against It.
Britain Has A £1 Billion Pandemic Plan.
More Children Got A First Vaccine. Millions Still Fell Out Of The System.
El Salvador Eliminated Trachoma. The Certificate Is Not The Finish Line.
Gonorrhoea Is Learning To Beat Ceftriaxone. Europe Must Move First.
Europe Built Seasonal COVID Campaigns. Most Older Adults Were Not Reached.
Ebola Has Passed 2,000 Cases. The Response Is Still Chasing It.
Ebola May Be Reaching Kisangani. Containment Cannot Stay Provincial.
Disaster Shelters Save Lives. Infection Control Cannot Be Improvised.
Neurology
See all →
Microglia Are Not a Shortcut to Alzheimer’s Certainty
Migraine Still Refuses a Simple Blood Test
A Blood Test Can See Risk. Policy Cannot Yet Hold It.
Down Syndrome Cannot Stay Outside Alzheimer’s Trials
Cataplexy Is Waiting on an FDA Clock
Tau Is Back. Certainty Is Not.
Alzheimer’s Treatment Moves Home. Risk Does Not.
When Dementia Takes Speech, Trials Must Catch Up
Child Mental Health Access Still Depends on the Facility
Huntington’s Gets Another Chance at Proof
Oncology
See all →
Liver Cancer Is Moving Beyond TACE Alone
ctDNA Is Becoming the New Argument Over Chemotherapy
The Most Powerful Oncology Tool This Week Was a Check-In
Myeloma Patients May Not Need Treatment Forever
Tissue-Agnostic Medicine Has a New Proof Point
Lung Cancer May Be Entering the Chemo-Replacement Fight
Breast Cancer Gets a New PI3K Pathway Option.
Bladder Cancer Surgery Just Became a System Test
A Blood Test Will Not Fix Colorectal Screening by Itself
